What I Learned After Losing My Partner to Polypharmacy

Most often, my public reflections center on the fair and ethical treatment of animals within the nonprofit that I founded and through my published works. That cause has shaped much of my work and my voice. But today, I step away from that familiar ground to reflect on something deeply personal — and tragically widespread.

Not until recently did I fully confront the significant harm that can arise when multiple psychiatric medications are layered simultaneously, despite having been prescribed. Like many, I had trusted that each prescription existed within a carefully coordinated system designed to safeguard the patient. Only after my partner, Nancy, took her own life at the age of fifty-four did I begin to understand how complex and fragile that balance can be.

In retracing her treatment history, I encountered a reality far more common than many realize: medications added over time, often by different providers, forming a dystopian pharmacological landscape whose cumulative effects are not always fully transparent. It was through that painful process that I came to recognize the concept known as polypharmacy — and the risks it can introduce when oversight, communication, or continuity falter.

Nancy battled depression and anxiety on and off for many years. Like countless others, she turned to the healthcare system for support — seeing multiple physicians, filling prescriptions, and placing her trust in their guidance. In the wake of her death, and in an effort to comprehend her final choice that still haunts me, I pored over her medical records, prescription logs, and psychiatric evaluations.

What I uncovered was alarming: a continuous stream of powerful medications prescribed by different providers across multiple facilities, often with little coordination or apparent consideration of the cumulative risks these drugs posed when combined.

Her loss forced me to confront a reality faced by countless families across the country: the quiet and often invisible accumulation of psychiatric prescriptions — one medication layered upon another — until the promise of relief becomes intertwined with dependence, instability, and risk. Polypharmacy is not rare. Research shows it is associated with increased adverse drug interactions, cognitive impairment, reduced treatment adherence, diminished quality of life, and elevated mortality risk (Maher et al., 2014; Wastesson et al., 2018).

Since her death, I have immersed myself in literature examining psychiatric pharmacology. The evidence presents a complicated picture. These medications can be lifesaving for some individuals. For others, particularly when combined or frequently adjusted, they can alter cognition, emotional regulation, and impulse control in unpredictable ways. Regulatory warnings acknowledge elevated suicidal ideation risk during certain treatment phases (U.S. Food and Drug Administration, 2007). These realities do not invalidate psychiatric care — but they demand transparency, coordination, and rigorous oversight.

Among the medications prescribed to Nancy were selective serotonin reuptake inhibitors (SSRIs), some of the most commonly prescribed treatments for depression and anxiety. For many patients these medications may provide meaningful relief, but their psychological effects are not universally benign. Studies and patient reports have described “emotional blunting” — a diminished ability to experience not only sadness and distress, but also pleasure, affection, motivation, and emotional connection — as well as apathy, agitation, and, in some individuals, a troubling sense of detachment. SSRIs also carry regulatory warnings concerning treatment-emergent suicidal thoughts and behaviors in children, adolescents, and young adults, particularly during early treatment and dose changes. This clearly underscores how profoundly medications intended to alter mood can affect the very emotional and psychological processes they are prescribed to stabilize.

Six weeks before her death, during a period of instability, Nancy fell and shattered her leg, requiring surgical repair and ultimately the insertion of a metal rod extending from knee to ankle. In response to her pain, she received fentanyl and was prescribed Norco — both highly addictive and dangerous even in small doses. When opioids such as fentanyl or hydrocodone in Norco are taken alongside antidepressants or other psychotropic medications, the dangers multiply exponentially. Patients can experience respiratory depression, profound sedation, cognitive impairment, and, in some cases, serotonin syndrome, a potentially life-threatening condition caused by excessive serotonin activity in the brain (Volpi-Abadie et al., 2013).

At the time, pain relief understandably took priority. However, why had adequate consideration not been given to alternatives in light of her psychiatric vulnerability? Modern pain management increasingly emphasizes multimodal approaches capable of reducing opioid exposure, including regional nerve blocks, localized anesthetic techniques, non-opioid pharmacologic strategies, and rehabilitative interventions. Evidence shows these approaches can effectively manage pain while improving safety outcomes (NIH HEAL Initiative, 2023). Opioids may sometimes be appropriate, but their deployment demands contextual caution — particularly in patients already navigating complex psychotropic regimens.

Over time, and prior to her having broken her leg, Nancy developed dependence — physiological and psychological — on medications intended to stabilize her. When prescriptions were discontinued, she sometimes sought another provider to maintain them. This revolving-door pattern reflects a systemic vulnerability that prescription monitoring frameworks were designed to reduce. Fragmented care systems are widely recognized contributors to unsafe polypharmacy. Patients seeing multiple prescribers are significantly more likely to experience adverse drug events due to interaction oversight or incomplete medication histories.

Nancy’s case, and numerous others like it across the country, raises serious concerns regarding systemic safeguards. In most states, clinicians and pharmacists are expected to review controlled-substance histories through Prescription Drug Monitoring Programs (PDMP) designed to detect overlapping prescriptions and misuse patterns. These systems have been shown to reduce inappropriate prescribing and overdose rates (Centers for Disease Control and Prevention, 2024). Yet Nancy’s experience suggests that coordination failures and fragmentation remain despite these safeguards.

These questions are difficult to separate from historical context. In the 1990s, opioids were widely marketed and prescribed under assurances of safety and low addiction risk — messaging that contributed to dramatic increases in prescribing and ultimately helped fuel a national crisis. By 2010, prescription opioid sales had quadrupled alongside overdose mortality (Centers for Disease Control and Prevention, 2022). That history should have reshaped clinical vigilance. Yet experiences like Nancy’s make one wonder whether institutional habits have evolved as fully as they should have.

I am left with questions that cannot be resolved retrospectively. Why were medications added without clear longitudinal review of cumulative exposure? Why was opioid therapy introduced without deeper apparent scrutiny of interaction risk? Why did monitoring mechanisms fail to prevent cycling between providers? These questions are reflections born from grief and from the recognition that systemic vulnerabilities affect many families beyond my own.

Nancy’s story is not reducible to pharmacology. Human suffering is never that simple. But neither can pharmacological influence be ignored when examining outcomes shaped by complex treatment environments. Psychiatric medications can save lives — yet they can also contribute to harm when prescribed without integration, caution, or continuity.

I cannot change what happened. I cannot recover answers that no longer exist. What remains is the responsibility to speak about these realities openly — to advocate for coordination, informed consent, interaction vigilance, and a healthcare culture that treats psychiatric prescribing with the same rigor applied to any life-critical intervention.

Because behind every prescription history is a human life. And lives depend on getting this right.